MedTrace Logo

Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)

NCT06707987 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23250

Last updated 2025-12-05

No results posted yet for this study

Summary

The aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Non-immunogenic staphylokinase

Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®

Sponsors & Collaborators

  • Federal Center of Cerebrovascular Pathology and Stroke, Russian Federation Ministry of Health

    collaborator OTHER

  • Supergene, LLC

    lead INDUSTRY

Principal Investigators

  • Nikolay A. Shamalov, MD, PhD Prof · Federal Brain and Neurotechnology Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2024-12-31
Completion
2025-02-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06707987 on ClinicalTrials.gov